Date Announcement
20/07/2021 Appendix 4C and Quarterly Activity Report
09/07/2021 Notification of cessation of securities – CDY
02/07/2021 MarketLit Investor Conference Presentation
17/06/2021 Cellmid Reports Record QVC Sales
10/06/2021 FGF5 Inhibitors Supply Agreement – Additional Information
10/06/2021 Release of Shares from Voluntary Escrow
08/06/2021 Supply Agreement for Cellmid’s FGF5 Inhibitors
02/05/2021 Investor Briefing and Presentation
30/04/2021 Chinese Import Permits Received
29/04/2021 Agreement Signed for Sale of Lyramid Limited
29/04/2021 Investor Briefing
23/04/2021 Appendix 4C and Quarterly Activity Report
01/04/2021 Appendix 2A
01/04/2021 CDYOA Top20 and Distribution List
01/04/2021 Change of Director’s Interest Notice – Cross
01/04/2021 Change of Director’s Interest Notice – Eck
01/04/2021 Change of Director’s Interest Notice – Gordon
01/04/2021 Change of Director’s Interest Notice – Halasz
31/03/2021 Proposed issue of Securities – CDY
31/03/2021 Rights Issue Closed with Strong Demand
31/03/2021 Supplementary Prospectus
25/03/2021 Cellmid receives R&D tax credit
12/03/2021 Dispatch of Rights Issue Documentation Completed
10/03/2021 Investor Presentation
09/03/2021 Commencement of the Trading of Rights on the ASX
08/03/2021 Appendix 3B
08/03/2021 Pause in Trading
08/03/2021 Rights Issue
08/03/2021 Rights Issue Prospectus
25/01/2021 Appendix 4C and Quarterly Activity Report
24/01/2021 Cellmid Receives First Order From Chinese Distributor
15/01/2021 Appendix 2A
04/01/2021 Final Director’s Interest Notice – King

 

 

Shop évolis®

Subscribe to our newsletter